IQGAP1 and gastric cancer: The study also found that ASAP1, through IQGAP1-activated CDC42, may upregulate EGFR-MAPK signaling, contributing to resistance to common gastric cancer chemotherapy drugs such as 5-fluorouracil and oxaliplatin (72).